Intercept Pharmaceuticals, Inc. (ICPT) Financial Statements (2024 and earlier)

Company Profile

Business Address 305 MADISON AVENUE
MORRISTOWN, NJ 07960
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments50,51784,709469,667652,622436,160414,917
Cash and cash equivalents50,51784,70958,15170,05543,24870,013
Short-term investments   411,516582,567392,912344,904
Restricted cash and investments5,3439,7007,5034,725  
Receivables26,86247,61741,54938,04425,69416,501
Inventory, net of allowances, customer advances and progress billings6,4628,6199,0278,4627,1083,480
Inventory6,4628,6199,0278,4627,1083,480
Prepaid expense      14,818
Other undisclosed current assets450,943351,64717,99517,46213,463(1,409)
Total current assets:540,127502,292545,741721,315482,425448,307
Noncurrent Assets
Inventory, Noncurrent6,4628,6199,0278,462  
Operating lease, right-of-use asset  6,119  
Property, plant and equipment9873,3776,3265,20210,41116,184
Other noncurrent assets5,1226,11912,32713,246  
Other undisclosed noncurrent assets1,0134977,0686,66116,33119,856
Total noncurrent assets:13,58424,73134,74833,57126,74236,040
TOTAL ASSETS:553,711527,023580,489754,886509,167484,347
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:116,977158,216106,89981,06339,57541,558
Interest and dividends payable8,6018,0378,037  
Employee-related liabilities24,51127,15426,48320,33527,118
Accounts payable14,23418,13224,59418,97511,7656,965
Accrued liabilities47,39960,23547,11427,5687,4757,475
Other undisclosed accounts payable and accrued liabilities55,34446,737    
Debt 109,569  6,456  
Deferred revenue and credits1,6211,782
Other undisclosed current liabilities3,5318,60172,17774,48673,00960,694
Total current liabilities:230,077166,817179,076162,005114,205104,034
Noncurrent Liabilities
Long-term debt and lease obligation223,104539,782560,582532,078371,250355,677
Long-term debt, excluding current maturities223,104539,782560,582532,078371,250355,677
Liabilities, other than long-term debt7,4534,3867,6849,2474,5828,250
Deferred revenue and credits8112,672
Other liabilities7,4534,3867,6849,2473,7715,578
Total noncurrent liabilities:230,557544,168568,266541,325375,832363,927
Total liabilities:460,634710,985747,342703,330490,037467,961
Equity
Equity, attributable to parent93,077(183,962)(166,853)51,55619,13016,386
Common stock423033333025
Additional paid in capital2,238,1792,308,6532,233,9372,176,1331,800,1441,486,690
Accumulated other comprehensive loss(8,256)(2,873)(2,477)(1,144)(2,259)(786)
Accumulated deficit(2,136,888)(2,489,772)(2,398,346)(2,123,466)(1,778,785)(1,469,543)
Total equity:93,077(183,962)(166,853)51,55619,13016,386
TOTAL LIABILITIES AND EQUITY:553,711527,023580,489754,886509,167484,347

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues285,710363,468312,690252,002179,804130,956
Revenue, net130,956
Cost of revenue(984)(3,100)(5,322)(4,212)(2,519)(1,371)
Cost of goods and services sold    (2,519)(1,371)
Gross profit:284,726360,368307,368247,790177,285129,585
Operating expenses(352,942)(416,127)(538,608)(560,217)(465,294)(466,568)
Other undisclosed operating income (loss) 86  2,5191,371
Operating loss:(68,216)(55,673)(231,240)(312,427)(285,490)(335,612)
Nonoperating income (expense)(106,642)(35,753)(43,640)(32,254)(23,752)(24,755)
Other nonoperating income6,5212,1554,4148,8906,7714,516
Interest and debt expense(91,778)16,511(48,054)(41,144)(30,523)(29,271)
Other undisclosed income from continuing operations before equity method investments, income taxes   48,05441,14430,52329,271
Loss from continuing operations before equity method investments, income taxes:(266,636)(74,915)(274,880)(344,681)(309,242)(360,367)
Other undisclosed income (loss) from continuing operations before income taxes91,778(16,511)    
Income (loss) from continuing operations before income taxes:(174,858)(91,426)(274,880)(344,681)(309,242)(360,367)
Other undisclosed loss from continuing operations      
Loss from continuing operations:(174,858)(91,426)(274,880)(344,681)(309,242)(360,367)
Loss before gain (loss) on sale of properties:(91,426)(274,880)(344,681)(309,242)(360,367)
Other undisclosed net income (loss)396,674     
Net income (loss) available to common stockholders, diluted:221,816(91,426)(274,880)(344,681)(309,242)(360,367)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):221,816(91,426)(274,880)(344,681)(309,242)(360,367)
Other comprehensive income (loss)(5,383)(396)(1,333)1,122 (358,351)
Comprehensive income (loss):216,433(91,822)(276,213)(343,559)(309,242)(718,718)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (1,473) 
Comprehensive income (loss), net of tax, attributable to parent:216,433(91,822)(276,213)(343,559)(310,715)(718,718)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: